Results 181 to 190 of about 82,478 (265)

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Scaffold‐free three‐dimensional culture of chronic lymphocytic leukaemia preserves B–T‐cell cross‐talk and enables drug response profiling

British Journal of Haematology, EarlyView.
Summary Chronic lymphocytic leukaemia (CLL) presents a complex biological and clinical landscape, strongly influenced by the tumour microenvironment (TME). To better capture this heterogeneity, we have developed patient‐derived lymphoma spheroids from CLL samples (CLL‐PDLS), which recapitulate the cross‐talk between malignant cells and the autologous ...
Heribert Playa‐Albinyana, Ariadna Giró, Juan A. Piñeyroa, Ferran Araujo‐Ayala, Cèlia Dobaño‐López, Sara Otín‐Sánchez, Elías Campo, Christine Bezombes, Patricia Pérez‐Galán, Dolors Colomer   +9 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Autophagy Inhibition by Fangji Huangqi Decoction Enhances Tumor Immunogenicity and Potentiates PD‐1 Blockade

Cancer Science, EarlyView.
In tumor cells, MHC‐I is typically degraded through autophagy, leading to reduced antigen presentation. However, Fangji Huangqi Decoction (FJHQ), acting as an autophagy inhibitor, suppresses lysosomal acidification, which in turn inhibits the degradation of MHC‐I. This results in increased surface expression of MHC‐I on tumor cells.
Yuxiao Jiang, Shiji Zeng, Dingye Wang, Junbo Jiang, Zhenzhen Li, Jingbi Li, Dan Chen, Xu Zhao, Zheng Ying, Yuehua Deng, Qianwei Cai, Silin Mai, Jiayi Zheng, Qiaohong Yang, Fang Liu, Biaoyan Du, Jianyong Xiao, Xiaoyi Liu, Kun Wang   +18 more
wiley   +1 more source

Triple‐Mutated HSV‐1 Expressing Soluble B7‐1 Plus CTLA‐4 Blockade Suppresses Lymph Node Metastasis in Tongue Cancer

Cancer Science, EarlyView.
In murine tongue cancer models, T‐mB7‐1, a triple‐mutated oncolytic herpes simplex virus type 1 (HSV‐1) engineered to express soluble B7‐1, suppresses cervical lymph node metastasis and improves survival, addressing a major prognostic determinant in oral squamous cell carcinoma (OSCC).
Akinari Sugauchi, Toshihiro Uchihashi, Hirotaka Ito, Miwako Iwai, Yuzuri Tsurumaki Sato, Kyoko Kurioka, Sena Zeynep Usta, Minoru Tanaka, Mikihiko Kogo, Susumu Tanaka, Hiroshi Fukuhara, Tomoki Todo   +11 more
wiley   +1 more source

Tumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐PD‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
New antibody‐based sandwich assays to measure plasma extracellular vesicle (EV) subsets derived from tumor tissues were developed. These EVs can be easily measured repeatedly at appropriate times. They may be useful as liquid biopsies for early cancer detection and for predicting efficacy following surgery and anti‐PD‐1 antibody in NSCLC patients ...
Tomonari Kinoshita, Shigeki Ohta, Seiki Wakui, Chihaya Maeda, Yuichiro Hayashi, Aya Misawa, Ryosuke Satomi, Shinnosuke Ikemura, Kenzo Soejima, Tomonori Yaguchi, Shotaro Maruyama, Hiroshi Kagamu, Yutaka Kawakami   +12 more
wiley   +1 more source

KPNA2 Drives Immunosuppression in Ovarian Cancer via CCL2/CCR2‐Dependent MDSC Recruitment

Cancer Science, EarlyView.
KPNA2 drives intratumoral MDSC accumulation and immunosuppression in ovarian cancer via the NF‐κB/CCL2/CCR2 axis. Mechanistically, KPNA2 facilitates NF‐κB/p65 nuclear translocation and induces CCL2 transcription, recruiting MDSCs to establish an immunosuppressive microenvironment.
Qingli Li, Jitong Zhao, Lu Yang, Lin Li, Ce Bian, Tao Yi, Huiqiong Huang, Gang Zheng, Xiaojuan Lin   +8 more
wiley   +1 more source

PD-L1 expression and soluble PD-L1 production in gastric cancer

, 2020
openaire   +1 more source

From Cold to Hot: Nanozyme‐Based Strategies for Reprogramming the Tumour Immunoenvironment

Cell Proliferation, EarlyView.
Nanozymes, with multi‐enzyme catalytic activities, reprogram the immunosuppressive tumour microenvironment by inducing immunogenic cell death, relieving hypoxia, and depleting antioxidants, effectively converting immunologically “cold” tumours into “hot” ones to boost cancer immunotherapy efficacy.
Yue Wang, Miao Xu, Yongshun Wang, Xuan Lin, Qiang Zhang, Xiaoning Lin, Xin Wu, Cheng Zhang, Wenhua Huang, Jianlin Shen   +9 more
wiley   +1 more source

From Tumour to Bloodstream: Advancing PD‐L1 Testing With Liquid Biopsies in Non‐Small Cell Lung Cancer

Cytopathology, EarlyView.
This review explores liquid biopsy as a complementary approach to tissue‐based PD‐L1 assessment in advanced NSCLC treated with immune checkpoint inhibitors. Focusing on circulating tumour cells, extracellular vesicles, and circulating tumour DNA, it summarises current evidence, technical challenges, and future perspectives for personalised ...
R. Leporati, V. Callegari, A. Ancora, M. Palmieri, B. Riccò, E. Cabitza, L. Trudu, K. Di Emidio, C. Chiavelli, A. Eccher, I. Mastrolia, V. Catani, S. Bettelli, G. Guaitoli, M. Dominici, F. Bertolini   +15 more
wiley   +1 more source